Supplement evidence

044 / 575Metabolic compound

Alpha-lipoic acid

View my plan →

The short answer

Studied for diabetic neuropathy symptoms, with benefits depending on route and trial.

Evidence and scope: Mixed evidence
This status does not grade the ingredient for every goal, outcome, or person.
Important limitation: It has not established disease prevention or longer life in healthy adults.
Before deciding: Can lower glucose and may interact with diabetes or thyroid treatment.

01 / PRACTICAL GUIDE

Dose, absorption, and combinations

These are indication-specific reference or studied ranges—not a personalized prescription. Start with the objective, then check the form, label, medicines, and health conditions.

Reference range by objective

Glucose-related research600 mg/day is commonly studied for diabetic neuropathy

Reference or studied range—not a personalized prescription. The product label or a clinician may specify a different dose.

Dose source ↗

More is not automatically better. A clinician or product label may specify a different amount.

Absorption / solubilityFat-soluble / lipid-based

Fat-soluble or lipid-based. Absorption generally improves with a meal containing fat.

How it is commonly taken

Absorption is higher away from food, but tolerance may dictate otherwise.

Do not combine casually

Glucose-lowering medicines, thyroid treatment, alcohol-related thiamin deficiency, and chemotherapy require review.

Dose and use source ↗

Dose and use links lead to primary or official source material. Search links are discovery tools, not proof that every returned paper applies.

02 / EVIDENCE

What the research says

We keep supportive, mixed, negative, safety, and contextual findings together. The headline never replaces the underlying papers.

4research papers in this ledger

35unique primary studies represented

2,500unique participants represented

These are audited counts for this JIVANA collection, not search-result totals. Participants are counted once when multiple papers use the same cohort; review papers are not added again to participant totals.

Open the research timelineResearch timeline

Entries are ordered by publication year. A study period appears only when the source reports it.

2023

Mixed or qualifiedPMID 37630823

Effects of Oral Alpha-Lipoic Acid Treatment on Diabetic Polyneuropathy

Symptoms, some disability measures, and satisfaction favored treatment with a dose-related trend, but objective vibration, nerve-conduction, and several impairment outcomes did not. Symptom relief is not proof of nerve repair.

Published: 2023n=1,242 participants10 primary studies represented

Study design and methods

Design: Systematic review and meta-analysis of 10 randomized trials
Population: 1,242 patients with diabetic sensorimotor polyneuropathy
Intervention: Oral alpha-lipoic acid 600–1,800 mg/day versus placebo
Outcome: Symptoms, disability, nerve function, and global satisfaction

Open research record ↗

2022

Mixed or qualifiedPMID 35812639

Effect of Alpha-Lipoic Acid in the Treatment of Diabetic Neuropathy

Only three of eight trials found significant symptom improvement and five did not, underscoring inconsistent results across routes, doses, and designs.

Published: 2022n=1,500 participants8 primary studies represented

Study design and methods

Design: Systematic review of eight randomized trials
Population: 1,500 patients with painful diabetic neuropathy
Intervention: Oral or intravenous alpha-lipoic acid versus an appropriate comparator
Outcome: Neuropathic symptoms and adverse events

Funding or conflict note: The trials overlap the route-specific syntheses and are excluded from aggregate totals.

Open research record ↗

2020

Mixed or qualifiedPMID 32091656

Alpha-lipoic acid supplementation and obesity measurements

Average weight fell about 2.3 kg and BMI about 0.49 kg/m², while waist circumference did not improve overall. These modest heterogeneous effects do not establish durable weight control or health outcomes.

Published: 202021 primary studies represented

Study design and methods

Design: Updated systematic review and dose-response meta-analysis of at least 21 randomized placebo-controlled trials
Population: Adults in weight, BMI, and waist-circumference trials
Intervention: Alpha-lipoic acid supplements versus placebo
Outcome: Weight, BMI, waist circumference, waist-to-hip ratio, and fat mass

Open research record ↗

2004

Supports a specific usePMID 14984445

Treatment of symptomatic diabetic polyneuropathy with alpha-lipoic acid

Three weeks of intravenous treatment improved symptoms and deficits with similar adverse-event rates. This medical infusion evidence cannot be assumed for oral supplements or long-term disease modification.

Published: 2004Duration: 3 weeksn=1,258 participants4 primary studies represented

Study design and methods

Design: Individual-trial meta-analysis of four randomized double-masked trials
Population: 1,258 patients with symptomatic diabetic polyneuropathy
Intervention: Intravenous alpha-lipoic acid 600 mg/day or placebo
Outcome: Total Symptom Score, neurologic deficits, responders, and adverse events

Funding or conflict note: The investigators searched the VIATRIS company trial database; this company-linked evidence base is an important limitation.

Open research record ↗

Unscreened discovery appendix—not evidence455 candidate publicationsSearch run: Aug 21, 2026

Complete for the displayed PubMed query at the search timestamp—not for all databases or every possible synonym. Candidates can be irrelevant, duplicate the same study, or report negative findings. They are never summed as evidence or participants until screened.

03 / SOURCES

Start with the source material

Official evidence overviewPubMed systematic-review index Live PubMed discovery searchNational Library of Medicine

The live search is for discovery only. Search-result counts change and are not included in the audited totals above.

Recent PubMed discovery recordsDirect links to the first 12 records returned by the reproducible search. These are discovery candidates—not reviewed summaries or a count of supportive findings.

04 / EXPERT CONTEXT

Expert context—not evidence

Expert positions are dated context—not scientific evidence. They never raise the evidence status or become consensus by repetition.

No direct, source-verified endorsement is currently recorded. Research authorship or discussion alone is not treated as endorsement.